Conmed AI Stock Analysis
Want to see CNMD full AI Analyst Report?
Conmed (CNMD) AI Stock Analysis
Conmed
(NYSE:CNMD)
The score is driven primarily by stable-but-not-robust financial performance: improving margins and leverage are offset by sharp TTM revenue decline and weakening cash-flow trend. The latest earnings call was supportive (maintained organic growth outlook and raised EPS guidance), while technicals are mixed with neutral momentum. Valuation is reasonable (mid-teens P/E) but the dividend yield is minimal.
Conmed (CNMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.47B
- Dividend Yield
- ―
- Average Volume (3M)
- 362.48K
- Price to Earnings (P/E)
- 20.5
- Beta (1Y)
- 0.56
- Revenue Growth
- 1.93%
- EPS Growth
- 16.93%
- Country
- US
- Employees
- 3,900
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Conmed Business Overview & Revenue Model
Company Description
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfo...
How the Company Makes Money
CONMED makes money primarily by selling medical devices and related surgical products to healthcare providers and distributors, generating revenue when its products are purchased for use in operating rooms and procedural settings. Its core revenue st...
Conmed Earnings Call Summary
The call was broadly positive. Third-quarter organic revenue growth was 6.7%, both major product lines grew organically, AirSeal, direct Buffalo Filter, and BioBrace performed well, and adjusted EPS exceeded expectations with higher full-year EPS guidance. The main negatives were declining reported revenue and adjusted EPS, lower free cash flow, weaker U.S. orthopedic and OEM smoke-evacuation sales, higher interest expense, tariff exposure, and a narrowed high end of revenue guidance. Overall, the highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, ConMed expects at least 5% organic constant currency revenue growth, with net sales growth of 5% to 5.5%, GI revenue of approximately $20 million, and changes in foreign currency exchange rates representing a tailwind to GAAP results of approximately $9 million; non GAAP adjusted diluted earnings per share are expected in the range of $4.54 to $4.61, adjusted gross margin of approximately 57.5%, adjusted interest expense of approximately $33.7 million, adjusted effective tax rate of approximately 24.5%, free cash flow of approximately $115 million, weighted average shares outstanding of 30.2 million, and $62 million allocated to share repurchase. Fourth-quarter guidance is GAAP net sales of between $364 million and $370 million, organic constant currency growth in the range of 5.1% to 6.8% excluding expected GI revenue of approximately $3.7 million and an FX tailwind of approximately $650 thousand, and adjusted EPS of between $1.23 and $1.30; the company also expects a $0.35 tariff impact ignoring the tariff refunds and 50 to 100 basis points of gross margin expansion with and without the refund.
Conmed Financial Statement Overview
Summary
Profitability and gross margin improved versus 2025 and leverage is trending better (debt-to-equity down to ~0.77 TTM), but near-term fundamentals are pressured by sharply negative TTM revenue growth (~-22%) and deteriorating free-cash-flow momentum despite still-positive FCF (~$133M TTM).
Income Statement
58NeutralBalance Sheet
64PositiveCash Flow
51Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.37B | 1.31B | 1.24B | 1.05B | 1.01B |
| Gross Profit | 783.38M | 725.38M | 733.03M | 676.25M | 571.25M | 568.04M |
| EBITDA | 211.37M | 176.49M | 251.63M | 172.00M | 27.56M | 179.33M |
| Net Income | 73.43M | 47.05M | 132.42M | 64.46M | -80.58M | 62.54M |
Balance Sheet | ||||||
| Total Assets | 2.30B | 2.33B | 2.31B | 2.30B | 2.30B | 1.77B |
| Cash, Cash Equivalents and Short-Term Investments | 47.97M | 40.82M | 24.46M | 24.30M | 28.94M | 20.85M |
| Total Debt | 815.87M | 834.94M | 905.78M | 991.25M | 1.05B | 684.66M |
| Total Liabilities | 1.24B | 1.29B | 1.34B | 1.47B | 1.55B | 980.58M |
| Stockholders Equity | 1.06B | 1.03B | 962.68M | 834.22M | 745.54M | 785.43M |
Cash Flow | ||||||
| Free Cash Flow | 132.69M | 150.88M | 153.88M | 106.32M | 11.58M | 96.90M |
| Operating Cash Flow | 146.31M | 170.69M | 166.97M | 125.35M | 33.37M | 111.77M |
| Investing Cash Flow | 6.69M | -20.96M | -13.08M | -20.03M | -249.53M | -14.87M |
| Financing Cash Flow | -143.11M | -135.82M | -151.00M | -110.43M | 225.00M | -101.55M |
Conmed Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNMD, the sentiment is Positive. The current price of 49.35 is above the 20-day moving average (MA) of 49.01, above the 50-day MA of 47.17, and above the 200-day MA of 41.96, indicating a bullish trend. The MACD of 1.08 indicates Negative momentum. The RSI at 52.05 is Neutral, neither overbought nor oversold. The STOCH value of 42.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNMD.
Conmed Risk Analysis
Conmed disclosed 37 risk factors in its most recent earnings report. Conmed reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksConmed Peers Comparison
Overall Rating
SYK75Outperform
SNN69Neutral
ZBH69Neutral
CNMD62Neutral
ENOV58Neutral
IART40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $118.29B | 32.74 | 15.61% | 1.13% | 7.87% | 22.82% | |
| 69Neutral | $12.96B | 20.40 | 12.25% | 2.56% | 5.26% | 31.02% | |
| 69Neutral | $19.19B | 25.65 | 6.05% | 0.95% | 6.98% | -2.22% | |
| 62Neutral | $1.47B | 20.46 | 7.07% | ― | 1.93% | 16.93% | |
| 58Neutral | $1.61B | -2.98 | -35.53% | ― | 3.28% | 62.02% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 40Underperform | $1.09B | 84.36 | 1.24% | ― | 0.84% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CNMD | Conmed Corporation | 49.35 | 7.51 | 17.95% | |
| ENOV | Enovis Corporation | 27.92 | -0.32 | -1.13% | |
| IART | Integra Lifesciences | 13.98 | 2.56 | 22.42% | |
| SNN | Smith & Nephew Snats | 30.97 | -0.74 | -2.33% | |
| SYK | Stryker Corp | 310.72 | -44.86 | -12.62% | |
| ZBH | Zimmer Biomet Holdings | 101.41 | 13.27 | 15.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
